(Funded by Boehringer Ingelheim RE-VERSE AD number, NCT02104947.). Idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.
Intracranial hemorrhage in patients taking anticoagulants and/or antiplatelets can have either a benign or malignant clinical course.Īll patients with intracranial hemorrhage taking dabigatran should be admitted for close neurological monitoring and serial imagingĮfficacy of Idarucizmab in Patients with Intracranial Hemorrhage Preconditioned with Dabigatran 6). In 2015 a specific reversal agent (idarucizumab) is in developmentĪndexanet alfa and aripazine are currently being evaluated in clinical trials In the event of bleeding, general supportive measures are recommended and if severe, the use of non-specific hemostatic agents such as prothrombin complex concentrates and recombinant factor VIIa must be considered. (Funded by Boehringer Ingelheim RE-VERSE AD number, NCT02104947.) In contrast to vitamin-K antagonists, which variably act via different coagulation factors, dabigatran provides effective, predictable, and reproducible anticoagulation with a low potential for drug-drug interactions and no drug-food interactions, without the need for routine coagulation monitoring or mandatory dose adjustment. Potent antithrombotic effects are achieved with direct thrombin inhibitors by specifically blocking the activity of thrombin, the central enzyme in the process responsible for clot (thrombus) formation.
0 kommentar(er)
